At the time of writing, MoonLake Immunotherapeutics [MLTX] stock is trading at $10.66, up 3.90%. An important factor to consider is whether the stock is rising or falling in short-term value. The MLTX shares have gain 23.09% over the last week, with a monthly amount drifted -79.74%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MoonLake Immunotherapeutics [NASDAQ: MLTX] stock has seen the most recent analyst activity on October 02, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Goldman downgraded its rating to Neutral on October 01, 2025, and kept the price target unchanged to $7. On September 30, 2025, downgrade downgraded it’s rating to Underperform but maintained its price target of $2 on the stock. Citigroup downgraded its rating to a Neutral but stick to its price target of $5 on September 30, 2025. Stifel downgraded its rating to a Hold but $13 remained the price target by the analyst firm on September 29, 2025. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on September 29, 2025, but kept the price target unchanged to $10. In a note dated September 29, 2025, Jefferies downgraded an Hold rating on this stock but restated the target price of $8.
For the past year, the stock price of MoonLake Immunotherapeutics fluctuated between $5.95 and $62.75. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. MoonLake Immunotherapeutics [NASDAQ: MLTX] shares were valued at $10.66 at the most recent close of the market. An investor can expect a potential return of 40.71% based on the average MLTX price forecast.
Analyzing the MLTX fundamentals
Gross Profit Margin for this corporation currently stands at -10.82% with Operating Profit Margin at -1972.27%, Pretax Profit Margin comes in at -1754.92%, and Net Profit Margin reading is -1732.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.42 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that MoonLake Immunotherapeutics [NASDAQ:MLTX] has a current ratio of 16.65. On the other hand, the Quick Ratio is 16.65, and the Cash Ratio is 11.21.
Transactions by insiders
Recent insider trading involved Bodenstedt Matthias, Chief Financial Officer, that happened on Oct 08 ’25 when 10870.0 shares were purchased. Former 10% Owner, Chen Bihua completed a deal on Sep 29 ’25 to sell 6.49 million shares. Meanwhile, Former 10% Owner Chen Bihua sold 5827.0 shares on Sep 30 ’25.
